Protembis GmbH

Come and join the team! #Protembis is a European medical device company active in the field of structural heart interventional cardiology. We strive to develop a simple and reliable solution to protect patients from brain injury during left-sided heart procedures, initially Transcatheter Aortic Valve Replacement (#TAVR). With our product, the #ProtEmbo® Cerebral Protection System, it is our goal to protect the brain, thereby improving patient quality of life and reduce overall healthcare costs associated with brain injury during those procedures. We are progressing well with compelling data on safety and performance coming from a European trial in TAVR. The company is also advancing with patient recruitment in an FDA approved Investigational Device Exemption (IDE) study. In order to support the regulatory team for international market access, Protembis is searching for a Regulatory Affairs Analyst. If you have an interest to learn more, please send your CV together with an adapted cover letter/email to Protembis at info@protembis.com. Ref: RA Analyst. Your application and related information will remain strictly confidential.

We are very pleased to announce the go-live of our new website (www.protembis.com), which focuses on the education and information needs for patients, physicians and other stakeholders who have an interest in learning more about the issues of new cerebral lesions during TAVR, and our next generation approach to mitigating the risk of brain injury during these procedures. #Protembis #ProtEmbo #Silentcerebrallesions #innovationinhealthcare #structuralheartprocedures #cerebralprotectionsystem Concept & Design: Frederick Bren d'Amour BRECO

As October comes to a close, we are delighted to celebrate the first #PROTEMBO IDE patient enrolled at Washington University in St. Louis Barnes-Jewish Hospital by the remarkable team of Alan Zajarias, Alex Brescia, Nathan Frogge, Tsuyoshi Kaneko. Significant thanks and recognition also go to the dedicated research team of Kyle Stumbaugh, Kelsey Gentry and James Hermeyer. #Protembis #TAVR #Silentcerebrallesions #StrokeinTAVR #Innovationinhealthcare

We are honoured to see the first patient treated in the #PROTEMBO IDE by the team at the Universitätsklinikum in Ulm, Germany. A team that has been heavily involved in the major cerebral protection trials over the last decade, led by Professor Wolfgang Rottbauer, and including Dr. Marvin Krohn-Grimberghe, Christian Liewald and Dr. Leonhard Schneider. Congratulations to everyone involved including the dedicated study research team. #TAVR #TAVI #Silentcerebrallesions #CerebralProtectionSystem #Protembis

#Protembis are proud to announce their sponsorship of a satellite ‘breakfast’ symposium at the upcoming #TCT2024. Cerebral Embolic Protection – A Next Generation Approach for Contemporary TAVR Practice. Monday, October 28, 2024, 6:30-7:30 AM (check-in 6:15AM) Room 207B, Level 2, Walter E. Washington Convention Centre The session will be Co-Chaired by Roxana Mehran and Samir Kapadia. It includes a stellar line-up of expert faculty and panel members, all of whom have contributed to shape our understanding of the CEP science, and evidence, over the last decade. See the detailed agenda: https://lnkd.in/ecWpBUeH If you are at TCT, then we warmly invite your attendance for what will be a hot topic presentation of the contemporary state of the art. Michael Dwyer Linke Axel Nicolas Van Mieghem Alexandra Lansky Ben Saville Mathew Williams Stephan Haussig Dr Matti Adam MD, and Joshua Rovin MD #PROTEMBO #TAVR #TAVI #Silentcerebrallesions #Innovationinhealthcare

We are honoured to announce the first patient treated in the #PROTEMBO IDE trial by Dr Matti Adam and his team at Uniklinik Köln, Germany. Substantial thanks and appreciation go to the outstanding work of the research team in reaching this milestone. #Protembis #TAVR #CEP #Silentcerebrallesions #Strokeprevention #Innovationinhealthcare

We are delighted to welcome Skyler Peffly RT(R) and Daniel M. to the #Protembis US Field Clinical Specialist team. Together, they bring a wealth of experience and will be instrumental in accelerating the momentum of the #PROTEMBO IDE trial while ensuring that the investigators continue to receive the highest level of training and meticulous case support. #TAVR #TAVI #Silentcerebrallesions #excellenceinhealthcare #cerebralprotection

Congratulations to the team at the University of Michigan in Ann Arbor for including their first patient in the #PROTEMBO Pivotal IDE trial. It is a great honour to work with the team of Stanley Chetcuti, Devraj Sukul, and Dr Robert Hawkins MD. Thank you for the efforts of the whole cardiovascular research team to reach this important milestone! #TAVR #TAVI #Cerebralprotection #Silentcerebrallesions #Protembis

An insightful publication that confirms that new silent cerebral lesions post-TAVR are not benign. We are proud to have made the decision, despite the added cost and complexity, to make Total New Lesion Volume Reduction assessed by DW MRI at 36hrs post procedure our superiority endpoint in the pivotal #PROTEMBO study. Come and learn more at our symposium at the upcoming #TCT2024. Roxana Mehran Kodali Susheel Stephan Haussig Dr Raj Makkar. #Protembis

Proud to announce the first patients included in the #PROTEMBO IDE study in Poland. Congratulations to Dariusz Jagielak, Radosław Targoński, Dr Darius Ciećwierz, Mateusz Bartoszek MD, and Mrs. Danuta Formella at Medical University of Gdansk. A fantastic collaboration, which continues to evolve following their previous experience as leading investigators in the #ProtEmbo-C European trial. #TAVR #TAVI #Silentcerebrallesions #Innovationinhealthcare #Protembis Medical University of Gdansk, Tri-City Central Animal Laboratory – Research and Service Centre